HSG 2024: SPK-10001 GLP-tox Poster
SPK-10001 induces a durable and safe reduction of HTT protein supporting further development in Huntington’s disease Download FIle
HSG 2024: SPK-10001 ROA Poster
Route to a safe delivery strategy of AAV-based gene therapy to the caudate and putamen of nonhuman primates Download FIle
HSG 2024: SPK-10001 Pharmacology poster
SPK-10001 AAV-based microRNA mediates non-allele specific reduction of HTT mRNA through RNA interfernce, demonstrating its potential for further preclinical development. Download FIle
NBDF 2024: Long-term Follow-up of Participants in the Phase I/II Trial of Dirloctocogene Samoparvovec (SPK-8011): Durable FVIII Expression and Clinically Meaningful Reduction of Bleeding
NBDF 2024 – Long-Term Follow-up of Participants in the Phase I/II Trial of Dirloctocogene Samoparvovec (SPK-8011): Durable FVIII Expression and Clinically Meaningful Reduction of Bleeding Powered By EmbedPress
WFH 2024 – Phase 1/2 QOL
WFH – SPK-8011-101 Phase 1/2 QOL Download FIle
WFH 2024 – Phase 1/2 Joint Health
WFH – SPK-8011-101 Phase 1/2 Joint Health Download FIle
CHDI 2024 – SPK-10001 Preclinical Poster
CHDI 2024 – SPK-10001 Preclinical Poster Download File
EAHAD 2024 – Durability in Mice Poster
EAHAD 2024 Poster:Analysis of Long-Term Expression Up To 72 Weeks of a Liver-Specific rAAV Gene Therapy Expressing the Human FVIII Transgene from Dirloctocogene Samoparvovec in Adult Mice Powered By EmbedPress
EAHAD 2024 – OSA Poster
EAHAD 2024 Poster:One Stage Assay Analysis Demonstrates that Gene Therapy-Derived Factor VIII (FVIII) from Dirloctocogene Samoparvovec Reduced Clot Times Compared to Endogenous FVIII at Comparable FVIII Levels Powered By EmbedPress
Spark Demo Post 1
Add Your Heading Text Here Download FIle